XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One ' s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric …

XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation EMERYVILLE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- XOMA…#ojemda #fda #raf #v600 #emeryville #xomacorporationxoma #nda #braf #owenhughes #xoma

Source: Reuters: Health - April 25, 2024 Category: Consumer Health News Source Type: news